Holen Sie sich die Stockscreener-App
208.87
2.44%
4.98
Handel nachbörslich:
207.01
-1.86
-0.89%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$203.89
Offen:
$203.52
24-Stunden-Volumen:
788.84K
Relative Volume:
0.64
Marktkapitalisierung:
$30.86B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
22.42
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
+1.08%
1M Leistung:
+4.88%
6M Leistung:
+6.84%
1J Leistung:
+62.00%
1-Tages-Spanne:
$201.00
$209.22
1-Wochen-Bereich:
$201.00
$210.02
52-Wochen-Spanne:
$129.40
$219.72
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
208.87 | 30.13B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,220.28 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.86 | 626.09B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
248.76 | 441.94B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
132.92 | 321.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.32 | 293.87B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’ - Pharma Voice
Insight Wealth Strategies LLC Has $7.20 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Biogen Inc. (BIIB) Stock Analysis: Uncovering A Potential 13% Upside - DirectorsTalk Interviews
Should Biogen’s Profit Squeeze Amid Rising New-Therapy Sales Prompt Action From Biogen (BIIB) Investors? - simplywall.st
Biogen Inc. (BIIB) Options Chain - Yahoo! Finance Canada
Biogen Inc (BIIB) Stock News Today - TradingKey
Biogen (BIIB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit? - simplywall.st
BIIB Stock Price Prediction 2025-2026 | Biogen Inc Forecast - 24/7 Wall St.
Biogen, Investors Reach Settlement Outline Over Alzheimer’s Drug - Bloomberg Law News
Biogen Completes RayThera Acquisition - Contract Pharma
Biogen closes deal for USD 1b buyout of RayThera - allsci.com
Biogen Completes Acquisition of RayThera Inc. - Biogen
Press Release: Biogen Completes Acquisition of RayThera Inc. - Moomoo
FMR LLC discloses 12.4% Biogen Inc (BIIB) stake totaling 18.29M shares - Stock Titan
Biogen Inc (BIIB) Director Lloyd Minor Sells 1,186 Shares - GuruFocus
Segall Bryant & Hamill LLC Makes New $1.02 Million Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. completed the acquisition of RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others. - marketscreener.com
Biogen (BIIB) director Lloyd Minor sells 1,186 shares under 10b5-1 plan - Stock Titan
Biogen Inc. $BIIB Stock Holdings Raised by Bank of America Corp DE - MarketBeat
Is Biogen Inc (BIIB) Overvalued After 3.3% Rally? GF Value Says - GuruFocus
Lloyd Minor (BIIB) files Form 144 for 593-share NASDAQ stock sale - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Biogen Inc. (BIIB) - The National Law Review
BIOGEN INC. SEC Filing (Aug 3, 2026) - Stock Titan
Biogen Inc. (BIIB) Stock Analysis: Potential 15% Upside Amidst Robust Drug Portfolio - DirectorsTalk Interviews
Healthcare of Ontario Pension Plan Trust Fund Sells 33,522 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Acquired by Amundi - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Hub Hires: Pierson Ferdinand, Biogen, FisherBroyles - Law360
Biogen stock price target raised to $251 by H.C. Wainwright - Investing.com
Why Biogen (BIIB) Is Up 5.8% After Q2 Revenue Beat And Raised 2026 GuidanceAnd What's Next - simplywall.st
Biogen Earnings: Growth Portfolio Outpaces Legacy Portfolio Erosion; Guidance Raised - Morningstar
Biogen’s 68% surge validates InvestingPro Fair Value analysis By Investing.com - Investing.com
Biogen flips '26 guidance from expected decline to sales increase - Fierce Pharma
Biogen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Is Biogen Inc (BIIB) Overvalued After Q2 Earnings With EPS of $0.66 and Revenue of $2,736 Million? GF Score: 69/100 - GuruFocus
Biogen reports Q2 2026: $2.74B revenue, GAAP EPS $0.66, Non‑GAAP EPS $3.60 - TradingView
Biogen Beats Estimates as New Medicines Overtake MS Business - Bloomberg.com
Biogen Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Biogen earnings on deck: Can Alzheimer’s drugs sustain momentum? By Investing.com - Investing.com Canada
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating - marketscreener.com
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo! Finance Canada
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS - AlphaStreet
BIIB|Biogen Inc|Price:200.140| - TradingKey
(BIIB) Volatility Zones as Tactical Triggers - Stock Traders Daily
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):